文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

免疫受损急性呼吸衰竭患儿插管前呼吸支持的使用与时长与死亡率增加相关

The Use and Duration of Preintubation Respiratory Support Is Associated With Increased Mortality in Immunocompromised Children With Acute Respiratory Failure.
PubMed 文献 · Crit Care Med · 2022-03-14
一句话结论在免疫受损(IC)及造血细胞移植(HCT)的急性呼吸衰竭患儿中,插管前使用经鼻高流量氧疗(HFNC)或无创正压通气(NIPPV)与PICU死亡率增加独立相关,且HCT患儿暴露超过6小时死亡率进一步增加。

这项回顾性多中心队列研究基于Virtual Pediatric Systems数据库82个中心,纳入1月龄至17岁、在PICU插管并接受有创机械通气≥24小时的患儿共5348例,其中1825例(34%)在插管前使用了HFNC和/或NIPPV。校正疾病严重程度后,插管前HFNC(aOR 1.33;95%CI 1.10-1.62)或NIPPV(aOR 1.44;95%CI 1.20-1.74)与PICU死亡率增加相关;在IC患儿(HFNC aOR 1.50;NIPPV aOR 1.76)和HCT患儿(HFNC aOR 1.75;NIPPV aOR 1.85)中同样相关,而无IC诊断患儿中未见相关。HCT患儿HFNC/NIPPV暴露超过6小时与死亡率增加相关(HFNC aOR 2.41;NIPPV aOR 2.53)。

要点

  • 在IC急性呼吸衰竭患儿中,插管前使用HFNC(aOR 1.50;95%CI 1.11-2.03)或NIPPV(aOR 1.76;95%CI 1.31-2.35)与PICU死亡率增加相关。
  • 在HCT患儿中,插管前使用HFNC(aOR 1.75;95%CI 1.07-2.86)或NIPPV(aOR 1.85;95%CI 1.12-3.02)与PICU死亡率增加相关。
  • 在无IC诊断的患儿中,插管前HFNC/NIPPV暴露与死亡率无显著相关。
  • HCT患儿插管前HFNC/NIPPV暴露超过6小时与死亡率增加相关(HFNC aOR 2.41;95%CI 1.05-5.55;NIPPV aOR 2.53;95%CI 1.04-6.15)。
  • 插管前HFNC/NIPPV使用率(中位数15%;范围0-63%)和PICU死亡率在不同中心间存在差异。

适用人群与场景

  • 1月龄至17岁在PICU插管并接受有创机械通气≥24小时的患儿。
  • 按免疫受损(IC)状态分层:50%无IC诊断,41%为IC但无既往造血细胞移植(HCT),9%有既往HCT。

研究设计与关键结果

  • 研究设计:回顾性多中心队列研究,纳入Virtual Pediatric Systems数据库82个中心。
  • 样本量:5348例PICU插管患儿中,1825例(34%)在插管前使用了HFNC和/或NIPPV。
  • 主要结果:与插管前未接受呼吸支持的患儿相比,插管前HFNC暴露与PICU死亡率增加相关(aOR 1.33;95%CI 1.10-1.62),NIPPV暴露与PICU死亡率增加相关(aOR 1.44;95%CI 1.20-1.74)。
  • 亚组结果:在IC患儿中,插管前HFNC(aOR 1.50;95%CI 1.11-2.03)和NIPPV(aOR 1.76;95%CI 1.31-2.35)与PICU死亡率增加相关;在HCT患儿中,HFNC(aOR 1.75;95%CI 1.07-2.86)和NIPPV(aOR 1.85;95%CI 1.12-3.02)与PICU死亡率增加相关。
  • 亚组结果:在无IC诊断的患儿中,插管前HFNC/NIPPV暴露与死亡率无显著相关。
  • 时长分析:HCT患儿插管前HFNC/NIPPV暴露超过6小时与死亡率增加相关(HFNC aOR 2.41;95%CI 1.05-5.55;NIPPV aOR 2.53;95%CI 1.04-6.15),对照为HCT患儿暴露不足6小时。
  • 中心差异:校正患者和中心特征后,插管前HFNC/NIPPV使用率(中位数15%;范围0-63%)和PICU死亡率在不同中心间存在差异。

证据类型、等级与局限

  • 证据类型:回顾性多中心队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在免疫受损(IC)及HCT的急性呼吸衰竭患儿中,插管前使用HFNC和/或NIPPV与PICU死亡率增加独立相关,临床决策时应考虑这一关联,避免延误插管。
  • 对于HCT患儿,插管前HFNC/NIPPV暴露超过6小时与死亡率进一步增加相关,提示应密切监测并评估早期插管指征。
  • 在无IC诊断的患儿中,插管前HFNC/NIPPV暴露与死亡率无显著相关。
  • 各中心插管前HFNC/NIPPV使用率和PICU死亡率存在差异,提示临床实践需结合本中心情况评估。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To determine the association between preintubation respiratory support and outcomes in patients with acute respiratory failure and to determine the impact of immunocompromised (IC) diagnoses on outcomes after adjustment for illness severity.

DESIGN: Retrospective multicenter cohort study.

SETTING: Eighty-two centers in the Virtual Pediatric Systems database.

PATIENTS: Children 1 month to 17 years old intubated in the PICU who received invasive mechanical ventilation (IMV) for greater than or equal to 24 hours.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: High-flow nasal cannula (HFNC) or noninvasive positive-pressure ventilation (NIPPV) or both were used prior to intubation in 1,825 (34%) of 5,348 PICU intubations across 82 centers. When stratified by IC status, 50% of patients had no IC diagnosis, whereas 41% were IC without prior hematopoietic cell transplant (HCT) and 9% had prior HCT. Compared with patients intubated without prior support, preintubation exposure to HFNC (adjusted odds ratio [aOR], 1.33; 95% CI, 1.10-1.62) or NIPPV (aOR, 1.44; 95% CI, 1.20-1.74) was associated with increased odds of PICU mortality. Within subgroups of IC status, preintubation respiratory support was associated with increased odds of PICU mortality in IC patients (HFNC: aOR, 1.50; 95% CI, 1.11-2.03; NIPPV: aOR, 1.76; 95% CI, 1.31-2.35) and HCT patients (HFNC: aOR, 1.75; 95% CI, 1.07-2.86; NIPPV: aOR, 1.85; 95% CI, 1.12-3.02) compared with IC/HCT patients intubated without prior respiratory support. Preintubation exposure to HFNC/NIPPV was not associated with mortality in patients without an IC diagnosis. Duration of HFNC/NIPPV greater than 6 hours was associated with increased mortality in IC HCT patients (HFNC: aOR, 2.41; 95% CI, 1.05-5.55; NIPPV: aOR, 2.53; 95% CI, 1.04-6.15) and patients compared HCT patients with less than 6-hour HFNC/NIPPV exposure. After adjustment for patient and center characteristics, both preintubation HFNC/NIPPV use (median, 15%; range, 0-63%) and PICU mortality varied by center.

CONCLUSIONS: In IC pediatric patients, preintubation exposure to HFNC and/or NIPPV is associated with increased odds of PICU mortality, independent of illness severity. Longer duration of exposure to HFNC/NIPPV prior to IMV is associated with increased mortality in HCT patients.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Lindell RB, Fitzgerald JC, Rowan CM, et al. The Use and Duration of Preintubation Respiratory Support Is Associated With Increased Mortality in Immunocompromised Children With Acute Respiratory Failure. Crit Care Med. 2022. PMID: 35275593. doi:10.1097/CCM.0000000000005535

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。